Pharmacy Brokerage Services / Confidential Index / PBS-0526
Live sell-side mandate · Project Citrus
An independent pharmacy scaling specialty at speed.
A confidential opportunity to acquire a high-growth independent community & specialty pharmacy in Southern California's Inland Empire — one that has nearly tripled revenue in three years on the strength of chronic-care and specialty therapies. Identity, licensure, and full financials are released to qualified buyers under a mutual non-disclosure agreement.
The opportunity
A neighborhood footprint with a specialty engine.
Project Citrus is an owner-led independent pharmacy that has grown well beyond a traditional retail counter. Its volume today is concentrated in high-value chronic-care and specialty categories — renal, cardiometabolic, and metabolic (GLP-1) therapies — dispensed to a loyal, delivery-driven patient base across the Inland Empire.
The result is a business with the recurring economics of specialty and the community relationships of an independent: broad prescriber support, high refill persistency, and genuine EBITDA. It is offered on a confidential, success-fee basis, with full detail released under NDA.
Revenue trajectory
Nearly tripled in three years — and still climbing.
≈ 72% three-year revenue CAGR · FY2024 and monthly detail in the CIM
What's driving the growth
Value a generalist buyer would underestimate.
The economics rest on category mix, payer diversity, and patient stickiness — not on a single relationship.
Specialty & chronic therapies
Renal, cardiometabolic (SGLT2), and metabolic (GLP-1) categories anchor a high-value, recurring script base.
Brand-led revenue
Roughly a quarter of scripts are brand drugs — and they generate the large majority of revenue, at about $209 per prescription.
Diversified payer mix
Medi-Cal Rx ~41%, Medicare Part D / MA ~31%, and commercial & other ~28% — no single payer dominates.
Broad prescriber base
More than 900 unique referring prescribers support the book, limiting dependence on any one physician.
Sticky, delivery-driven patients
A ~74% delivery rate and a 64% refill rate underpin durable, predictable recurring revenue.
Real, defensible margin
~$1.5M adjusted EBITDA in FY2025 (~12% of revenue), built on a documented owner add-back schedule.
At a glance
The blind-teaser snapshot.
Released under NDA
Entity name and licensure, exact location, FY2024 and monthly financials, payer contracts, prescriber and patient concentration, and the full confidential information memorandum are shared only with qualified buyers under a mutual non-disclosure agreement.
Project Citrus · PBS-0526
Request the confidential memorandum.
Qualified buyers receive the full CIM — identity, financials, and diligence materials — under a mutual NDA. Start with a confidential conversation.
Request the CIM under NDA